Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 21, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-19
DOI
10.1007/s11883-019-0809-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Case report: The efficiency and safety of lomitapide in a homozygous familial hypercholesterolemic child
- (2019) Ana Paula M. Chacra et al. Journal of Clinical Lipidology
- Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
- (2019) Tawfeg Ben-Omran et al. ADVANCES IN THERAPY
- Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2019) Federica Fogacci et al. DRUGS
- Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia
- (2018) Raul D. Santos ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lomitapide in homozygous familial hypercholesterolemia
- (2018) Simona Sperlongano et al. Journal of Cardiovascular Medicine
- LONG-TERM SAFETY AND EFFICACY OF LOMITAPIDE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THREE-YEAR DATA FROM THE LOMITAPIDE OBSERVATIONAL WORLDWIDE EVALUATION REGISTRY (LOWER)
- (2018) James Underberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
- (2018) Dirk J. Blom et al. Orphanet Journal of Rare Diseases
- Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
- (2018) Atsushi Nohara et al. Journal of Atherosclerosis and Thrombosis
- Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
- (2018) Laurens F. Reeskamp et al. ATHEROSCLEROSIS
- Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol
- (2017) Gilbert R Thompson et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
- (2017) Mariko Harada-Shiba et al. Journal of Atherosclerosis and Thrombosis
- ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
- (2017) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress
- (2017) Ying Liu et al. Cell Reports
- The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis
- (2017) Robert Leipold et al. European Journal of Preventive Cardiology
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
- (2017) Frederick J Raal et al. Lancet Diabetes & Endocrinology
- Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study
- (2016) Frederick J. Raal et al. ATHEROSCLEROSIS
- Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives
- (2016) Claudia Sanna et al. ATHEROSCLEROSIS
- MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia
- (2016) Genovefa D Kolovou et al. Journal of Atherosclerosis and Thrombosis
- LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
- (2016) Dirk J. Blom et al. Journal of Clinical Lipidology
- Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
- (2016) P. Barton Duell et al. Journal of Clinical Lipidology
- Evolocumab for the treatment of homozygous familial hypercholesterolaemia
- (2016) Dirk Jacobus Blom et al. Expert Opinion on Orphan Drugs
- The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – A post-hoc analysis of a Phase 3, single-arm, open-label trial
- (2015) C. Stefanutti et al. ATHEROSCLEROSIS
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances
- (2014) Claudia Stefanutti et al. Current Atherosclerosis Reports
- Hypobetalipoproteinemia and abetalipoproteinemia
- (2014) Francine K. Welty CURRENT OPINION IN LIPIDOLOGY
- Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
- (2014) Barbara Sjouke et al. EUROPEAN HEART JOURNAL
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies
- (2014) M. M. Page et al. INTERNAL MEDICINE JOURNAL
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
- (2014) JoAnn D. Flaim et al. Journal of the American Heart Association
- Progression to Hepatitis and Fibrosis Secondary to Lomitapide Use—Reply
- (2014) Frank M. Sacks et al. JAMA Internal Medicine
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
- (2013) Gregory S. Thomas et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- (2012) Frederick J. Raal et al. ATHEROSCLEROSIS
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
- (2012) Evan A. Stein et al. CIRCULATION
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- (2012) Maartje E. Visser et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
- (2012) Marina Cuchel et al. LANCET
- Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
- (2012) Mary P. McGowan et al. PLoS One
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
- (2011) Frederick J. Raal et al. CIRCULATION
- Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia
- (2011) M. E. Visser et al. DIABETOLOGIA
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
- (2010) Fatima Akdim et al. AMERICAN JOURNAL OF CARDIOLOGY
- Apolipoprotein B synthesis inhibition: results from clinical trials
- (2010) Maartje E Visser et al. CURRENT OPINION IN LIPIDOLOGY
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- (2010) Fatima Akdim et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Overexpression of apolipoprotein-B improves cardiac function and increases survival in mice with myocardial infarction
- (2009) Truls Råmunddal et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia
- (2008) Daniel M. Kolansky et al. AMERICAN JOURNAL OF CARDIOLOGY
- Abetalipoproteinemia: two case reports and literature review
- (2008) Rola Zamel et al. Orphanet Journal of Rare Diseases
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now